智通财经APP讯，绿新生物科技(01084)发布公告，经初步审阅现有可得资料(包括但不限于本集团截至2026年6月30日止6个月(报告期间)的未经审核综合管理账目)后，董事会谨此通知本公司股东(股东)及有意投资者，于报告期间，本公司预期取得本公司拥有人应占亏损净额介乎约人民币100万元至人民币400万元，而截至2025年6月30日止6个月的本公司拥有人应占亏损净额为人民币1207万元。
本集团的表现有所改善，主要是由于卡拉胶产品销量因本集团具竞争优势的定价策略而增加，推动报告期间的收益及毛利增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.